The C-mer gene is induced by Epstein-Barr virus immediate-early protein BRLF1

被引:13
|
作者
Li, YL
Mahajan, NP
Webster-Cyriaque, J
Bhende, P
Hong, GK
Earp, HS
Kenney, S
机构
[1] Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Sch Dent, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA
[5] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA
关键词
D O I
10.1128/JVI.78.21.11778-11785.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
BRLF1 (R) is one of two Epstein-Barr virus (EBV) immediate-early proteins that mediate the switch from the latent to the lytic form of viral replication. In this report, we show that R induces expression of the cellular C-mer gene in a variety of cell lines. C-mer expression was detected in lymphoblastoid cells immortalized with wild-type EBV but not in lymphoblastoid cells immortalized with an EBV that had BRLF1 deleted. Oral hairy leukoplakia tongue tissue, which contains the lytic form of EBV replication, also has enhanced C-mer expression. C-mer is a receptor tyrosine kinase activated by the ligand Gas6. C-mer is required for phagocytosis of apoptotic debris by monocytes/macrophages and retinal pigment epithelial cells and is capable of producing an antiapoptotic signal. Modulation of the C-mer signal transduction cascade by a variety of different approaches did not alter the ability of R to induce lytic EBV gene transcription. Therefore, C-mer activation may be important for some other aspect of lytic EBV infection.
引用
收藏
页码:11778 / 11785
页数:8
相关论文
共 50 条
  • [21] Characterization of the Epstein-Barr virus BRRF1 gene, located between early genes BZLF1 and BRLF1
    Segouffin-Cariou, C
    Farjot, G
    Sergeant, A
    Gruffat, H
    JOURNAL OF GENERAL VIROLOGY, 2000, 81 : 1791 - 1799
  • [22] Inhibition of IFN-γ signaling by an Epstein-Barr virus immediate-early protein
    Morrison, TE
    Mauser, A
    Wong, A
    Ting, JPY
    Kenney, SC
    IMMUNITY, 2001, 15 (05) : 787 - 799
  • [23] The BRRF1 early gene of Epstein-Barr virus encodes a transcription factor that enhances induction of lytic infection by BRLF1
    Hong, GK
    Delecluse, HJ
    Gruffat, H
    Morrison, TE
    Feng, WH
    Sergeant, A
    Kenney, SC
    JOURNAL OF VIROLOGY, 2004, 78 (10) : 4983 - 4992
  • [24] Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation
    Chang, LK
    Liu, ST
    NUCLEIC ACIDS RESEARCH, 2000, 28 (20) : 3918 - 3925
  • [25] Sequence Analysis of EBV Immediate-Early Gene BZLF1 and BRLF1 in Lymphomas
    Yang, Ying
    Jia, Yuping
    Wang, Yun
    Wang, Xiaofeng
    Sun, Zhifu
    Luo, Bing
    JOURNAL OF MEDICAL VIROLOGY, 2014, 86 (10) : 1788 - 1795
  • [26] Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product
    Adamson, AL
    Kenney, SC
    VIROLOGY, 1998, 251 (01) : 187 - 197
  • [27] THE EPSTEIN-BARR-VIRUS BRLF1 IMMEDIATE-EARLY GENE-PRODUCT TRANSACTIVATES THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 LONG TERMINAL REPEAT BY A MECHANISM WHICH IS ENHANCER INDEPENDENT
    QUINLIVAN, EB
    HOLLEYGUTHRIE, E
    MAR, EC
    SMITH, MS
    KENNEY, S
    JOURNAL OF VIROLOGY, 1990, 64 (04) : 1817 - 1820
  • [28] DIRECT BRLF1 BINDING IS REQUIRED FOR COOPERATIVE BZLF1/BRLF1 ACTIVATION OF THE EPSTEIN-BARR-VIRUS EARLY PROMOTER, BMRF1
    QUINLIVAN, EB
    HOLLEYGUTHRIE, EA
    NORRIS, M
    GUTSCH, D
    BACHENHEIMER, SL
    KENNEY, SC
    NUCLEIC ACIDS RESEARCH, 1993, 21 (08) : 1999 - 2007
  • [29] Elevation of antibody against Epstein-Barr virus genes BRLF1 and BZLF1 in nasopharyngeal carcinoma
    Yoshizaki, T
    Miwa, H
    Takeshita, H
    Sato, H
    Furukawa, M
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2000, 126 (02) : 69 - 73
  • [30] Elevation of antibody against Epstein-Barr virus genes BRLF1 and BZLF1 in nasopharyngeal carcinoma
    Tomokazu Yoshizaki
    Hiroko Miwa
    Hajime Takeshita
    Hiroshi Sato
    Mitsuru Furukawa
    Journal of Cancer Research and Clinical Oncology, 2000, 126 (2) : 69 - 73